Durvalumab and Ablative Radiation in Small Cell Lung Cancer
Status:
Not yet recruiting
Trial end date:
2027-10-01
Target enrollment:
Participant gender:
Summary
This this study is for individuals who have treatment-naïve extensive-stage small cell lung
cancer (small cell lung cancer that wont respond to treatment). Doctors leading this study
hope to learn if combining durvalumab, carboplatin and etoposide with hyofractionated
ablative radiation therapy (radiation focused on certain parts of the body) will help treat
your cancer and improve how long you can live with extensive-stage small cell cancer without
it getting worse (progression-free survival). Your participation in this research will last
about 48 months.
Durvalumab along with chemotherapy has been approved by the Food and Drug Administration
(FDA) for the treatment of small cell lung cancer along with chemotherapy. This study is
testing the addition of radiation to durvalumab and chemotherapy.